RxDoctor Payments Data

Gaston Perez

Family Medicine · Bluffton, SCNPI 1629188586

Payments from drug & device makers

$8,545in general payments, 2019–2025

Across 478 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$876
  • Novo Nordisk$796
  • Johnson & Johnson$574
  • Amgen$451
  • Otsuka America Pharmaceutical, Inc.$401
  • plus $4K from 50 others

What the payments were for

  • Food & beverage$8,537100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,545 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$99,875
Medicare patients
144
Services billed
1,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$70,369
FarxigaDapagliflozin Propanediol82$66,476
EliquisApixaban69$61,176
RybelsusSemaglutide23$27,778
MounjaroTirzepatide21$21,831
XareltoRivaroxaban18$19,321
JanuviaSitagliptin Phosphate12$15,148
LinzessLinaclotide18$12,368
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl69$10,577
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,222
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$9,954
MyrbetriqMirabegron12$5,601
ProgesteroneProgesterone, Micronized122$4,520
Rosuvastatin Calcium227$4,312
Nebivolol Hcl79$4,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$796$98,14867 claims
AstraZenecaFarxiga, Breztri Aerosphere$876$76,43094 claims
PfizerEliquis$162$61,17669 claims
Lilly USA, LLCMounjaro$227$21,83121 claims
Johnson & JohnsonXarelto$574$19,32118 claims
MerckJanuvia$62$15,14812 claims
AbbVieLinzess$1,022$12,36818 claims
GSKTrelegy Ellipta$306$10,22212 claims
Astellas Pharma US IncMyrbetriq$51$5,60112 claims
Acella Pharmaceuticals, LLCNp Thyroid$19$1,30531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Bluffton

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →